Synthesis and cytotoxic evaluation of substituted sulfonyl-n- hydroxyguanidine derivatives as potential antitumor agents

Journal of Medicinal Chemistry

Volumn 40, Issue 14, 1997, Pages 2276-2286

  Chern, Ji Wang ^a,f   Leu, Yu Ling ^b   Wang, Shan Shue ^c   Jou, Ruwen ^c   Lee, Chin Fen ^c   Tsou, Pei Chie ^c   Hsu, Shih Chung ^c   Liaw, Yen Chywan ^d   Lin, Hua Mei ^e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c DEVELOPMENT CENTER FOR BIOTECHNOLOGY   (Taiwan)

^d INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^e TAO YUAN GENERAL HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 CHLOROPHENYL) 3 (4 METHYLPHENYLSULFONYL)UREA; ANTINEOPLASTIC AGENT; N (4 CHLOROPHENYL) N' [(BENZO[2,1,3]THIADIAZOL 4 YL)SULFONYL] N'' HYDROXYGUANIDINE; N (4 CHLOROPHENYL) N' [[3,5 DICHLORO 4 (2 CHLORO 4 NITROPHENOXY)PHENYL]SULFONYL] N'' HYDROXYGUANIDINE; N (4 CHLOROPHENYL) N' [[3,5 DICHLORO 4 (4 NITROPHENOXY)PHENYL]SULFONYL] N'' HYDROXYGUANIDINE; SULFONYL N HYDROXYGUANIDINE DERIVATIVE; SULOFENUR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CYTOTOXICITY; DRUG CONFORMATION; DRUG STRUCTURE; MELANOMA CELL; NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; CALORIMETRY; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; GUANIDINES; HUMANS; KB CELLS; MAGNETIC RESONANCE SPECTROSCOPY; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030740236     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9607818     Document Type: Article

References (34)

1. Larner, J. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, 6th ed.; Gilman, A. G., Goodman, L. S., Gilman, A., Eds.; Macmillan Publishing Co., Inc.: New York, 1980; p 1510.
2. Howbert, J. J.; Grossmann, C. S.; Crowell, T. A.; Rieder, B. J.; Harper, R. W.; Kramer, K. E.; Tao, E. V.; Aikins, J.; Poore, G. A.; Riezel, S. M.; Grindey, G. B.; Shaw, W. N.; Todd, G. C. Novel agents effective against solid tumors: the diarylsulfonylureas. synthesis, activities, and analysis of quantitative structure-activity relationships. J. Med. Chem. 1990, 33, 2393-2407.
3. Houghton, P. J.; Bailey, F. C.; Germain, G. S.; Grindey, G. B.; Howbert, J. J.; Houghton, J. A. Studies on the cellular pharmacology of N-(4-methylphenylsulfonyl)-N′-(4-chlorophenyl)urea. Biochem. Pharmacol. 1990, 39, 1187-1192.
4. Houghton, P. J.; Bailey, F. C.; Germain, G. S.; Grindey, G. B.; Witt, B. C.; Houghton, J. A. N-(5-Indanylsulfonyl)-N′-(4-chlorophenyl)urea, a novel agent equally cytotoxic to nonproliferating human colon adenocarcinoma cells. Cancer Res. 1990, 50, 318-322.
5. Taylor, C. W.; Alberts, D. S.; Ketcham, M. A.; Satterlee, W. G.; Holdsworth, M. T.; Plezia, P. M.; Peng, Y. M.; McCloskey, T. M.; Roe, D. J.; Hamilton, M.; Salmon, S. E. Clinical pharmacology of a novel diarylsulfonylurea anticancer agent. J. Clin. Oncol. 1989, 7, 1733-1740.
6. Hainsworth, J. D.; Hande, K. R.; Satterlee, W. G.; Kuttesch, J.; Johnson, D. H.; Grindey, G.; Jackson, L. E.; Greco, F. A. Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641). Cancer Res. 1989, 49, 5217-5220
7. Munshi, N. C.; Seitz, D. E.; Fossella, F.; Lippman, S. M.; Einhorn, L. H. Phase II study of sulofenur (LY186641), a novel antineoplastic agent, in advanced non-small cell lung cancer. Proc. Am. Assoc. Cancer Res. 1991, 32, 189.
8. Hande, K. R.; Kuttesch, J.; Hamilton, M.; Satterlee, W.; Jackson, L.; Grindey, G.; Hainsworth, J. D. Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans. Cancer Res. 1990, 50, 3910-3914.
9. Brien, M. E.; Hardy, J.; Tan, S.; Walling, J.; Peters, B.; Hatty, S.; Wiltshaw, E. A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer. Cancer Chemother. Pharmacol. 1992, 30, 245-248.
10. Grindey, G. B.; Boder, G. B.; Harper, R. W.; Howbert, J. J.; Poore, G. A.; Rieder, B. J.; Shaw, W. N.; Todd, G. C.; Worzalla, J. F. Identification of diarylsulfonylureas as novel antitumor agents. Proc. Am. Assoc. Cancer Res. 1986, 27, 277.
11. Grindey, G. B.; Boder, G. B.; Grossman, J. J.; Howbert, J. J.; Poore, G. A.; Shaw, W. N.; Todd, G. C.; Worzalla, J. F. Further development of diarylsulfonylureas as novel anticancer drugs. Am. Assoc. Cancer Res. 1987, 28, 309.
12. Grindey, G. B. Identification of diarylsulfonylureas as novel anticancer drugs. Proc. Am. Assoc. Cancer Res. 1988, 29, 535.
13. Houghton, P. J.; Bailey, F. C.; Houghton, J. A.; Murti, K. G.; Howbert, J. J.; Grindey, G. B. Evidence for mitochondrial localization of N-(4-methylphenylsulfonyl)-N′-(4-chlorophenyl)-urea in human colon adenocarcinoma cells. Cancer Res. 1990, 50, 664-668.
14. Thaker, J. H.; Chapin, C.; Berg, R. H.; Ashmun, R. A.; Houghton, P. J. Effect of antitumor diarylsulfonylurea on in vivo and in vitro mitochondrial structure and functions. Cancer Res. 1991, 51, 6286-6291.
15. Ruch, G. F.; Rinzel, S.; Boder, G.; Heim, R. A.; Toth, J. E.; Ponsler, G. D. Effects of diarylsulfonylurea antitumor agents on the function of mitochondria isolated from rat liver and GC3/c1 cells. Biochem. Pharmacol. 1992, 44, 2387-2394.
16. Toth, J. E.; Ray, T.; Deeter, J. Synthesis and resolution of sulfonimidamide analogs of sulfonylureas. J. Org. Chem. 1993, 58, 3469-3472.
17. Chern, J.-W.; Rong, J.-G. 1,2,4-Benzothiadiazine 1,1-dioxide. V: synthesis of built-in hydroxyguanidine tricycles as potential anticancer agents. Tetrahedron Lett. 1991, 32, 2935-2938.
18. Chern, J.-W.; Liaw, Y.-C.; Chen, C.-S.; Rong, J.-G.; Huang, C.-L.; Chan, C-H.; Wang, A. H.-J. Studies on 1,2,4-benzothiadiazine 1,1-dioxides VII and quinazolinones IV: Synthesis of novel built-in hydroxyguanidine tricycles as potential anticancer agents. Heterocycles 1993, 36, 1091-1103.
19. Young, C. W.; Schochetman, G.; Hodas, S.; Balis, M. E. Inhibition of DNA synthesis by hydroxyurea: structure-activity relationships. Cancer Res. 1967, 27, 535-540.
20. Tai, A. W.; Lien, E. J.; Lai, M. M. C.; Khwaja, T. A. Novel N-hydroxyguanidine derivatives as anticancer and antiviral agents. J. Med. Chem. 1984, 27, 236-238.
21. T'ang, A.; Lien, E. J.; Lai, M. M. C. Optimization of the schiff base of N-hydroxy-N′-aminoguanidine as anticancer and antiviral agents. J. Med. Chem. 1985, 28, 1103-1106.
22. Adamson, R. H. Hydroxyguanidine - a new antitumor drug. Nature 1972, 236, 400-401.
23. Saenger, W. Principles of Nucleic Acids Structure; Springer-Verlag: Berlin, 1987.
24. Stuwart, J. J. P. 1987, MOPAC Version 5.0, QCPE No. 455.
25. Stewart, J. J. P. Optimization of parameters for semiempirical methods. J. Comput. Chem. 1989, 10, 209-215.
26. Sheldrick, G. M. In Cristallographic Computing 3; Sheldrick, G. M., Kruger, C., Goddard, R., Eds.; Clarendon Press: Oxford, 1985; pp 175-189.
27. Sheldrick, G. M. 1993, SHELX03, Program for the refinement of crystal structures, Univ. of Gottingen, Germany.
28. Johson, C. K. (1971). ORTEP. Report ORNL-3794, revised. Oak Ridge National Laboratory, Oak Ridge, TN.
29. James, C.; William, G. D.; Adi, F. G.; John, D. M.; James, B. M. Evaluation of a Tetrazolium-based Semiautomated Colorimetric Assay: Assessement of Chemosensitivity Testing. Cancer Res. 1987, 47, 936-942.
30. Michael, C. A.; Dominic, A. S.; Anne, M.; Miriam, L. H.; Maciej, J. C.; Donald, L. F.; Bety, J. A.; Joseph, G. M.; Robert, H. S.; Michael, R. B. Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay. Cancer Res. 1988, 48, 589-601.
31. Rubinstein, L. V.; Shoemaker, R. H.; Paull, K. D.; Simon, R. M.; Tosini, S.; Skehan, P.; Scudiero, D. A.; Monks, A.; Boyd, M. R. Comparison of in Vitro Anticancer-Drug-Screening Data Generated With a Tetrazolium Assay Versus a Protein Assay Against a Diverse Panel of Human Tumor Cell Lines. J. Natl. Cancer Inst. 1990, 82, 1113-1118.
32. McMipley, R. J.; Burns-Horwitz, P. E.; Czerniak, P. M.; Diamond, M. A.; Miller, J. L. D.; Page, R. J.; Dexter, D. L.; Chen, S. F.; Sun, J. H.; Behrens, C. H.; Seitz, S. P.; Gross, J. L. Efficacy of DMP840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity. Cancer Res. 1994, 54, 159-164.
33. Zhou, Y.; Ling, Y. H.; Van, N. T.; Priebe, W.; Roman, P. S. Antitumor activity of free and liposome-entrapped Annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res. 1994, 54, 1479-1484.
34. Goldin, A.; Venditti, J. M.; MacDonald, J. S.; Muggia, F. M.; Henney, J. E.; Devita, J. T., Jr. Current results of the screening program at the division of cancer treatment, National Cancer Institute. Eur. J. Cancer 1981, 17, 129-142.